January - December
* Net sales increased by 36 % to SEK 74.6 million (54.8).
* The operating result for the year increased to SEK 3.1 million
(-8.6), an improvement of SEK 11.7 million as compared to the
previous year. The net result increased to SEK 2.6 million (-8.8).
* The net result per share amounted to SEK 0.11 million (-0.37).
* Liquid assets amounted to SEK 16.3 million (16.8).
* Orders continuously strong on the European market.
* New application for body fluids launched in the fall.
* An evaluation of a potential future establishment on the
Japanese market was initiated.
* CellaVision was admitted to trading on First North by the
Stockholm Stock Exchange on May 28.
October - December
* Net sales for the fourth quarter increased by 25 % to SEK 19.4
million (15.5).
* The operating result amounted to SEK 3.0 million (-1.3) and the
net result per share to SEK 0.12 million (-0.05).
* The gross profit increased to 73 % (66).
Important events after the reporting period
* As of January 1 the agreement with the distributor Sysmex was
altered, allowing CellaVision to sell parallel to Sysmex on the
American market.
CellaVision in short
(MSEK) Q4 2007 Q4 2006 2007 2006
Net sales 19.4 15.5 74.6 54.8
Gross profit 14.1 10.2 45.3 32.0
Operating result 3.0 -1.3 3.1 -8.6
Net result 2.8 -1.2 2.6 -8.8
Cash flow 0.1 -1.4 -0.4 -0.8
CEO's comment"It is pleasing to present a positive result for the year and a sales
increase of 36 %. A key reason for this is that we further fortified
our position on markets where we are already well established, most
importantly in Europe. In order to increase the volume of sales in
the North American market, in 2008 we will invest in our own
organization and sell in parallel to our American distributor. In
addition we are evaluating a potential establishment on the Japanese
market," says Yvonne Mårtensson, CEO of CellaVision."Another milestone for the company was the initiation of trade at
First North, which makes us more visible on the financial market. All
of this combined makes me hopeful of CellaVision's development during
2008 and the coming years."
For more information please contact:
Yvonne Mårtensson, CEO. Phone: +46 708 33 77 82, e-mail:
yvonne.martensson@cellavision.se
Johan Wennerholm, CFO. Phone: +46 708 33 81 68, e-mail:
johan.wennerholm@cellavision.se
